Additionally, the significant association between immune checkpoint genes and PROS1 indicated that targeting PROS1 might increase the efficacy of immunotherapy in LGG, which was consistent with the Tumor Immune Dysfunction and Exclusion (TIDE) results. The gene discussed is PROS1; the disease is neoplasm.